# SUCCESSOR-2 (NCT05552976)

> A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05552976
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Relapsed or Refractory Multiple Myeloma
- Interventions: Mezigdomide; Carfilzomib; Dexamethasone
- Enrollment: 606
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- YouTube: 51
- X threads: 35
- Podcasts: 15
- X videos: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=successor-2-nct05552976

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05552976", "email": "<work email>"}; the inbox owner confirms by the emailed link.